We provide you with 20 years of free, institutional-grade data for ABEO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ABEO. Explore the full financial landscape of ABEO stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$1,068,422
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Alland Leila | Sale | -11,000 | $5.92 | $65,087 | 2026-07-02 |
| Silverstein Christine Berni | Sale | -18,160 | $5.71 | $103,695 | 2026-06-15 |
| Vazzano Joseph Walter | Sale | -49,338 | $5.43 | $267,881 | 2026-06-09 |
| Vasanthavada Madhav | Sale | -9,620 | $5.43 | $52,232 | 2026-06-09 |
| Seshadri Vishwas | Sale | -56,344 | $5.43 | $305,920 | 2026-06-09 |
| O'Malley Brendan M. | Sale | -11,131 | $5.43 | $60,436 | 2026-06-09 |
| Alvino Mark | Sale | -6,500 | $5.46 | $35,463 | 2026-05-22 |
| Crombez Eric | Sale | -26,143 | $5.53 | $144,636 | 2026-05-15 |
| Vasanthavada Madhav | Sale | -5,548 | $5.96 | $33,073 | 2026-05-11 |
| Goldan Keith A. | Grant, award...etc | 32,751 | 2026-04-07 | ||
| Seshadri Vishwas | Sale | -29,985 | $4.38 | $131,481 | 2026-03-31 |
| Vazzano Joseph Walter | Sale | -785 | $4.76 | $3,737 | 2026-03-16 |
| Silverstein Christine Berni | Sale | -20,070 | $5.09 | $102,168 | 2026-02-04 |
| Wuchterl Donald A. | Sale | -14,814 | $5.09 | $75,412 | 2026-02-02 |
| Crombez Eric | Sale | -16,284 | $5.09 | $82,895 | 2026-02-02 |
| Alland Leila | Sale | -18,065 | $5.09 | $91,962 | 2026-02-02 |
| Alvino Mark | Sale | -2,000 | $5.09 | $10,181 | 2026-02-02 |
| Wuchterl Donald A. | Grant, award...etc | 37,313 | 2026-01-27 | ||
| Zeiher Bernhardt G | Grant, award...etc | 37,313 | 2026-01-27 | ||
| Crombez Eric | Grant, award...etc | 37,313 | 2026-01-27 | ||
| Silverstein Christine Berni | Grant, award...etc | 37,313 | 2026-01-27 |
The information provided in this report about ABEO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Abeona Therapeutics Inc(NASDAQ:ABEO) 
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated...
Website: http://www.abeonatherapeutics.com
Founded: 1974
Full Time Employees: 88
Sector: Healthcare
Industry: Biotechnology